SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access. Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic...
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic synergy with SK bioscience Sustainable growth expected, backed by European commercial...